Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 20/20 | 1.00 |
| ▸ | PSEN2 | P49810 | 20/20 | 1.00 |
| ▸ | APH1B | Q8WW43 | 20/20 | 1.00 |
| ▸ | NCSTN | Q92542 | 20/20 | 1.00 |
| ▸ | APH1A | Q96BI3 | 20/20 | 1.00 |
| ▸ | PSENEN | Q9NZ42 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5520409 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5517916 | 0.94 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5517955 | 0.94 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5524727 | 0.91 | PSEN1 (0.84) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5515329 | 0.91 | PSEN1 (0.84) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1874986 | 0.90 | PSEN1 (0.91) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5517861 | 0.90 | PSEN1 (0.82) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5521954 | 0.90 | PSEN1 (0.82) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1880980 | 0.89 | PSEN1 (0.89) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5515362 | 0.89 | PSEN1 (0.89) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208488-B2 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2007-04-24 | — | — | US | claimed |
| EP-1680406-A1 | N-SUBSTITUTED BENZENE SULFONAMIDES | Elan Pharmaceuticals, Inc. (US) | 2006-07-19 | — | — | EP | claimed |
| US-20050165003-A1 | Treating Alzheimer's Disease; 4-Chloro-N-(4-hydroxy-3-methoxy-benzyl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamide for example; gamma secretase inhibitors; inhibition of beta-amyloid synthesis with minimal inhibition of Notch Signaling | ELAN PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | claimed |
| WO-2005042489-A1 | N-SUBSTITUTED BENZENE SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165003-A1 | Treating Alzheimer's Disease; 4-Chloro-N-(4-hydroxy-3-methoxy-benzyl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamide for example; gamma secretase inhibitors; inhibition of beta-amyloid synthesis with minimal inhibition of Notch Signaling | BACE1, PSEN1, BACE2 | PSEN1 2/4885PSEN2 5/4885APH1B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.